µÏÍþ¹ú¼Ê



µÏÍþÖÆµÏÍþ¹ú¼Ê µÏÍþÖÆµÏÍþ¹ú¼Ê

¼ò ¤™
  • ¼ò
  • ·±
  • EN
¤œ
Ïà¹ØÁ´½Ó
  • ½­ËÕºÀÉ­µÏÍþ¹ú¼ÊÒµ¼¯ÍÅÓÐÏÞ¹«Ë¾¥Y
ÐÂÎÅ·¢²¼
Press Release
Ê×Ò³  >  ÐÂÎÅÖÐÐÄ  >  ÐÂÎÅ·¢²¼
INT J MOL SCI |µÏÍþÖÆµÏÍþ¹ú¼ÊæÚÀ´ÃÀ?ͨ¹ýË«ÖØ»úÖÆ¼ÓËÙÌÇÄò²¡ÉË¿ÚÓúºÏ
·¢²¼ÈÕÆÚ£º2025/03/31
×ÖºÅ
½üÈÕ£¬µÏÍþÖÆµÏÍþ¹ú¼ÊÒȸßѪÌÇËØÑùëÄ-1ÊÜÌ弤¶¯¼Á£¨GLP-1RA£©ÖÜÖÆ¼Á¾ÛÒÒ¶þ´¼ÂåÈûÄÇëÄ£¨ÉÌÆ·Ãû£ºæÚÀ´ÃÀ?£©¶ÔÌÇÄò²¡ÉË¿ÚÓúºÏµÄÓ°Ïì¼°ÆäDZÔÚ»úÖÆÑо¿½á¹û·¢±íÔÚInternational Journal of Molecular Sciences£¨¼ò³ÆINT J MOL SCI£¬¡¶¹ú¼Ê·Ö×Ó¿ÆÑ§ÔÓÖ¾¡·£©£¬Ê״νÒʾÁËæÚÀ´ÃÀ?ͨ¹ýË«ÖØ»úÖÆ¼ÓËÙÌÇÄò²¡ÉË¿ÚÓúºÏ¡ª¡ªÏµÍ³ÐÔ¿¹Ñ×µ÷½ÚÓëѪ¹ÜÄÚÆ¤×æÏ¸°û£¨EPCs£©¹¦ÄÜÐÞ¸´£¬´Ó¶øÎªÌÇÄò²¡ÂýÐÔÉË¿ÚÖÎÁÆÌṩÁËвßÂÔ¡£[1]

ÌÇÄò²¡ÊÇÈ«Çò·¶Î§ÄÚµ¼ÖÂËÀÍöºÍ²Ð¼²µÄÖ÷ÒªÔ­ÒòÖ®Ò»£¬ÆäѪ¹Ü²¢·¢Ö¢£¨ÈçÂýÐÔÉË¿ÚÓúºÏÑÓ³Ù£©ÊÇÁÙ´²ÖÎÁƵÄÖØÒªÌôÕ½¡£ÌÇÄò²¡ÉË¿ÚÓúºÏÕϰ­µÄ»úÖÆ¸´ÔÓ£¬Éæ¼°ÂýÐÔÑ×Ö¢¡¢Ñª¹ÜÐÂÉú²»×㡢Ѫ¹ÜÄÚÆ¤×æÏ¸°û£¨EPCs£¬¼´Ñª¹ÜÄÚÆ¤Ï¸°ûµÄǰÌåϸ°û£©¹¦ÄÜÊÜËð£¬ÒÔ¼°ÏßÁ£ÌåÑõ»¯Ó¦¼¤µÈ¡£Ëæ×ÅÌÇÄò²¡»¼²¡ÂʵÄÉÏÉý£¬Ñ°ÕÒÓÐЧµÄÉ˿ڷÀÖβßÂÔÏÔµÃÓÈΪÆÈÇС£
½üÄêÀ´£¬GLP-1RAÒò¼æ¾ß½µÌǺÍÐÄѪ¹Ü±£»¤×÷Óñ¸ÊܹØ×¢¡£±±¾©Ð­ºÍÒ½Ôº¿ÎÌâÑо¿Ð¡×éͨ¹ýÌåÄÚÍâʵÑ飬ϵͳÆÀ¹ÀÁËæÚÀ´ÃÀ?¶ÔÌÇÄò²¡ÉË¿ÚÓúºÏµÄÓ°Ïì¼°ÆäDZÔÚ»úÖÆ£¬Ñо¿½á¹û·¢±íÔÚINT J MOL SCI¡£[1]

¸ÃÑо¿Ê¹ÓÃСÊó½¨Á¢ÉË¿ÚÄ£ÐÍ£¬±È½Ï½ÓÊÜæÚÀ´ÃÀ?ÖÎÁƵÄÌÇÄò²¡Ð¡Êó£¨ÌÇÄò²¡ÖÎÁÆ×飩Óëδ½ÓÊÜÖÎÁƵÄÌÇÄò²¡Ð¡Êó£¨ÌÇÄò²¡²»ÖÎÁÆ×飩ÒÔ¼°Õý³£Ð¡Ê󣨶ÔÕÕ×飩µÄÉË¿ÚÓúºÏÇé¿ö¡£´ËÍ⣬»¹Í¨¹ýÌåÍâʵÑéÆÀ¹ÀæÚÀ´ÃÀ?¶ÔEPCs¹¦ÄܵÄÓ°Ïì¡£Ñо¿·¢ÏÖ£¬æÚÀ´ÃÀ?¾ßÓÐÒÔÏÂ×÷Óãº[1]
  • ¸ÄÉÆ´úлÎÉÂÒ£ºÏà±ÈÌÇÄò²¡²»ÖÎÁÆ×飬½ÓÊÜæÚÀ´ÃÀ?ÖÎÁƵÄÌÇÄò²¡Ð¡ÊóÌåÖØÃ÷ÏÔϽµ£»æÚÀ´ÃÀ?»¹¿Éͨ¹ýÌá¸ßÒȵºËØÃô¸ÐÐԺ͸ÄÉÆÆÏÌÑÌÇÇå³ýÄÜÁ¦»º½âÌÇÄò²¡´úлÎÉÂÒ¡£
  • ¼ÓËÙÉË¿ÚÓúºÏ£ºÏà±ÈÕý³£Ð¡Êó£¬ÌÇÄò²¡Ð¡ÊóµÄÉË¿ÚÓúºÏËÙ¶ÈÏÔÖø½µµÍ¡£È»¶ø£¬½ÓÊÜæÚÀ´ÃÀ?ÖÎÁƵÄÌÇÄò²¡Ð¡ÊóÏà±Èδ½ÓÊÜÖÎÁƵÄÌÇÄò²¡Ð¡ÊóµÄÓúºÏËÙ¶ÈÃ÷ÏÔÌáÉý¡£
  • µ÷½ÚϵͳÐÔÑ×Ö¢£ºÑªÇåµ°°×ÖÊ×éѧÏÔʾ£¬æÚÀ´ÃÀ?ÖÎÁƺó´ÙÑ×Òò×Ó£¨ÈçCCL2¡¢CCL20£©ÏÔÖøÏµ÷£¬¿¹Ñ×Òò×ÓIL-5Éϵ÷¡£ÌáʾæÚÀ´ÃÀ?¿ÉÄÜͨ¹ýÒÖÖÆÂýÐÔÑ×Ö¢£¬¸ÄÉÆÑª¹ÜÐÞ¸´Î¢»·¾³£¬´Ó¶ø´Ù½øÉË¿ÚÓúºÏ¡£
  • »Ö¸´EPCs¹¦ÄÜ£ºÌåÍâʵÑé±íÃ÷£¬¸ßÌÇ/¸ßÖ¬»·¾³ÏÔÖøÒÖÖÆEPCsµÄ¹ÜÐγɺÍÇ¨ÒÆÄÜÁ¦£¬¶øæÚÀ´ÃÀ?¿É²¿·Ö»Ö¸´ÕâЩ¹¦ÄÜ¡£æÚÀ´ÃÀ?¶ÔÓÚEPCs¹¦Äܵı£»¤»úÖÆ£¬Ò»·½ÃæÊÇÄܹ»½µµÍÏßÁ£Ìå»îÐÔÑõ£¨ROS£©Éú³É²¢¸ÄÉÆÏßÁ£ÌåºôÎü¹¦ÄÜ£»ÁíÒ»·½ÃæÊÇͨ¹ýÔöÇ¿ÏßÁ£Ìå×ÔÊɶøÇå³ýÊÜËðÏßÁ£Ì壬´Ó¶øÎ¬³Öϸ°ûÎÈ̬¡£
¼ÈÍùÓÐÌåÍâÊÔÑéÏÔʾ£¬ÂåÈûÄÇëÄ¿Éͨ¹ýSIRT3/Foxo3ÐźÅͨ·¸ÄÉÆEPCsËðÉ˺ÍÏßÁ£Ì幦ÄÜÕϰ­[2]¡£·¢±íÓÚMedComm£¨IF£º10.7£©µÄÊ׸öÖйúÈËȺGLP-1RAÐÄѪ¹Ü½á¾Ö´óÐÍÕæÊµÊÀ½çÑо¿£¨FLYING£©£¬´ÓÁÙ´²ÉÏÖ¤Ã÷ÁËÂåÈûÄÇëĿɽµµÍ2ÐÍÌÇÄò²¡»¼ÕßÐÄѪ¹Üʼþ·¢Éú·çÏÕ[3]¡£
±¾Ñо¿ÎªÂåÈûÄÇëÄÓÃÓÚÌÇÄò²¡Ñª¹Ü²¢·¢Ö¢µÄÖÎÁÆÌṩÁËÀíÂÛÖ§³Ö£¬ÎªÌÇÄò²¡ÂýÐÔÉË¿ÚÖÎÁÆÌṩÁËвßÂÔ£¬Ò²ÍØÕ¹ÁËGLP-1RAµÄÁÙ´²Ó¦ÓÃǰ¾°£¬ÀýÈçÓÃÓÚÆäËûÏßÁ£Ì幦ÄÜÕϰ­Ïà¹Ø¼²²¡µÄÖÎÁÆ¡£Î´À´Ñо¿½«½øÒ»²½Ì½Ë÷ÆäÔÚÈËÌåÖеÄÁÆÐ§¼°·Ö×Óµ÷¿ØÍøÂç¡£
²Î¿¼ÎÄÏ×£º
[1] Ding  Z, Yang C, Zhai X, Xia Y, Liu J, Yu M. Polyethylene Glycol Loxenatide  Accelerates Diabetic Wound Healing by Downregulating Systemic  Inflammation and Improving Endothelial Progenitor Cell Functions. Int J  Mol Sci. 2025;26(5):2367.
[2]  Yuan J, Wang Y, Wang D, Yan H, Wang N. Loxenatide attenuates  ROS-mediated vascular endothelial progenitor cell damage and  mitochondrial dysfunction via SIRT3/Foxo3 signaling pathway. J Biochem Mol Toxicol. 2023;37(11):e23452.

[3]  Li J, Tian Y, Li L, et al. Once-weekly glucagon-like peptide receptor  agonist polyethylene glycol loxenatide protects against major adverse  cardiovascular events in patients with type 2 diabetes: a multicenter  ambispective cohort study (FLYING trial). MedComm (2020). 2025;6(2):e70094.


ÉùÃ÷£º

1¡¢±¾¹«¸æ½ö¹©Ò½ÁÆÎÀÉúרҵÈËÊ¿²ÎÔÄ£¬·Ç¹ã¸æÓÃ;¡£

2¡¢µÏÍþÖÆµÏÍþ¹ú¼Ê²»ÍƼöÈκÎδ»ñÅúµÏÍþ¹ú¼ÊƷʹÓúÍ/»òδ»ñÅúÊÊÓ¦Ö¢ÓõÏÍþ¹ú¼Ê£¬Ò಻¶ÔÈκεÏÍþ¹ú¼ÊÆ·ºÍ/»òÊÊÓ¦Ö¢×÷ÍÆ¼ö¡£

3¡¢±¾¹«¸æÖÐÉæ¼°µÄÐÅÏ¢½ö¹©²Î¿¼£¬Çë×ñ´ÓÒ½Éú»òÆäËûÒ½ÁÆÎÀÉúרҵÈËÊ¿µÄÒâ¼û»òÖ¸µ¼¡£Ò½ÁÆÎÀÉúרҵÈËÊ¿×÷³öµÄÈκÎÓëÖÎÁÆÓйصľö¶¨Ó¦¸ù¾Ý»¼ÕߵľßÌåÇé¿ö²¢×ñÕÕµÏÍþ¹ú¼ÊƷ˵Ã÷Êé¡£

4¡¢ÈçÐèÁ˽⹫˾ÈκβúÆ·¡¢Ò½ÁÆ»ò¼²²¡µÄÏà¹ØÐÅÏ¢£¬ÇëÎñ±Ø×ÉѯҽÁÆÎÀÉúרҵÈËÊ¿¡£



¹ØÓÚµÏÍþ

µÏÍþÖÆµÏÍþ¹ú¼ÊÊÇÖйúÁìÏȵĴ´ÐÂÇý¶¯ÐÍÖÆµÏÍþ¹ú¼ÊÆóÒµ£¬ÒÔ¡¸³ÖÐø´´Ð£¬Ìá¸ßÈËÀàÉúÃüÖÊÁ¿¡¹ÎªÊ¹Ãü£¬ÖØµã¹Ø×¢¿¹Ö×Áö¡¢¿¹¸ÐȾ¡¢ÖÐÊàÉñ¾­ÏµÍ³¡¢´úл¼°×ÔÉíÃâÒßµÈÖØ´ó¼²²¡ÖÎÁÆÁìÓò¡£½ØÖÁĿǰ£¬¹«Ë¾ÒÑÉÏÊÐ7¿î´´ÐµÏÍþ¹ú¼Ê£¬ÐγÉÁ˷ḻµÄ²úÆ·¹ÜÏß¡£µÏÍþÖÆµÏÍþ¹ú¼ÊÁ¬Ðø¶àÄêλ¾ÓÈ«ÇòÖÆµÏÍþ¹ú¼ÊÆóÒµ°ÙÇ¿¡¢ÖйúÒ½µÏÍþ¹ú¼ÊÑз¢²úÆ·Ïß×î¼Ñ¹¤ÒµÆóҵǰ3Ç¿£¬Êǹú¼ÒÖØµã¸ßм¼ÊõÆóÒµ¡¢¹ú¼Ò¼¼Êõ´´ÐÂʾ·¶ÆóÒµ¡£µÏÍþÖÆµÏÍþ¹ú¼ÊÓÚ2019Äê6ÔÂÔÚÏã¸ÛÁª½»Ëù¹ÒÅÆÉÏÊУ¨¹ÉƱ´úÂ룺03692.HK£©¡£
¸ü¶àÐÅÏ¢Çë·ÃÎÊ£º/¡£



ǰհÐÔ˵Ã÷

±¾ÎÄÖ¼ÔÚÌṩÓйء°µÏÍþÖÆµÏÍþ¹ú¼Ê¼¯ÍÅÓÐÏÞ¹«Ë¾¡±»òÆä×Ó¹«Ë¾µÈ¹ØÁª·½£¨Í³³Æ¡°¹«Ë¾¡±£©µÄÏà¹ØÐÅÏ¢£¬²»¹¹³É¹«Ë¾ÐÅÏ¢Åû¶»òͶ×ÊÍÆ¼ö¡£

±¾ÎÄËù·¢²¼µÄÐÅÏ¢ÖпÉÄÜ»á°üº¬Ä³Ð©Ç°Õ°ÐÔ±íÊö£¬ÀýÈçÉæ¼°ÒµÎñºÍ²úƷǰ¾°£¬»ò¹«Ë¾¼Æ»®¡¢ÈÏÖª¡¢Ô¤ÆÚ¼°²ßÂÔ¡£ÕâЩ±íÊöÊǽ¨Á¢ÔÚÍÆ²âÐÔ¼ÙÉèµÄÊý¾Ý»ù´¡ÉϵÄÔ¤²â£¬²¢·ÇÊǶÔδÀ´·¢Õ¹µÄ±£Ö¤£¬ÒòÆäÐÔÖÊʹȻ¾ùÊÜÏà¹Ø·çÏպͲ»È·¶¨ÒòËØÓ°Ï죬ÆäÖв¿·Ö»¹²»Êܹ«Ë¾¿ØÖÆÇÒÄÑÒÔÔ¤ÁÏ£¬Í¶×ÊÕß½øÐÐͶ×ʾö²ßʱӦ½÷É÷ʹÓá£ÔÚʹÓá°ÖÂÁ¦ÓÚ¡±¡°Ô¤ÆÚ¡±¡°ÏàÐÅ¡±¡°Ô¤²â¡±¡°ÆÚÍû¡±¼°ÆäËûÀàËÆ´ÊÓï½øÐбíÊöʱ£¬·²Ó빫˾ÓйصÄÐÅÏ¢±íÊö£¬¾ùÊôÓÚǰհÐÔ±íÊö¡£¹«Ë¾²¢ÎÞÒåÎñ¸üлòÐÞ¸ÄÕâЩǰհÐÔ±íÊö£¬¹«Ë¾¡¢¹«Ë¾¶­Ê¡¢¹ÍÔ±¡¢´úÀí¸Å²»³Ðµ£ÒòÈκÎǰհÐÔ±íÊö²»ÄÜʵÏÖ»ò±ä³É²»ÕýÈ·¶øÒýÖµÄÈκÎÔðÈΡ£

±¾ÐÂΟåÖеÄËùÓÐÐÅÏ¢½ö¼°ÓÚÐÂΟ巢²¼Ö®ÈÕ£¬ÎÞÂÛÊÇ·ñ³öÏÖÐÂ×ÊÁÏ¡¢Î´À´Ê¼þ»òÆäËûÇé¿ö£¬³ý·Ç·¨ÂÉÒªÇ󣬹«Ë¾²¢ÎÞÔðÈλòÒåÎñ¸üлòÐ޸ĸõÈÐÅÏ¢¡£Í¶×ÊÕßÒ˲ÎÕÕµÏÍþÖÆµÏÍþ¹ú¼Ê£¨03692.HK£©¹«¸æ¼°²Æ±¨£¬ÒÔ»ñÈ¡½öÓëÉÏÊй«Ë¾ÓйصÄÐÅÏ¢¡£

¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿